Same Syndrome, Different Causes and Treatment: Path to Diagnosis and Management of Two Interesting Cases of Acquired von Willebrand Syndrome

Marta Monti; Evita Massari; Marco Rosetti; Alice Clementoni; Giovanni Poletti; Melania Olivieri; Daniela Conti; Tommaso Fasano

doi:10.1055/s-0043-1772837

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2024; 50(02): 307-309
DOI: 10.1055/s-0043-1772837

Letter to the Editor

Same Syndrome, Different Causes and Treatment: Path to Diagnosis and Management of Two Interesting Cases of Acquired von Willebrand Syndrome

Authors

Marta Monti

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Evita Massari

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Marco Rosetti

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Alice Clementoni

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Giovanni Poletti

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Melania Olivieri

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Daniela Conti

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy
Tommaso Fasano

¹Clinical Pathology Unit, Hub Laboratory, AUSL della Romagna, Cesena, Italy

Abstract

Full Text

References

References
1 Franchini M, Lippi G, Favaloro EJ. Advances in hematology. Etiology and diagnosis of acquired von Willebrand syndrome. Clin Adv Hematol Oncol 2010; 8 (01) 20-24
2 Franchini M, Lippi G. Recent acquisitions in acquired and congenital von Willebrand disorders. Clin Chim Acta 2007; 377 (1–2): 62-69
3 Colonne CK, Reardon B, Curnow J, Favaloro EJ. Why is misdiagnosis of von Willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations. J Blood Med 2021; 12: 755-768
4 Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
5 Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica 2020; 105 (08) 2032-2037
6 Mannucci PM, Lombardi R, Bader R. et al. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984; 64 (03) 614-621
7 Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY. Acquired von Willebrand syndrome in monoclonal gammopathy - a scoping review on hemostatic management. Res Pract Thromb Haemost 2021; 5 (02) 356-365
8 Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol 2005; 66 (04) 422-430
9 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
10 Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14 (02) 401-436
11 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92 (08) 2707-2711
12 Michiels JJ, van Vliet HH. Acquired von Willebrand disease in monoclonal gammapathies: effectiveness of high-dose intravenous gamma globulin. Clin Appl Thromb Hemost 1999; 5 (03) 152-157